Organization
Shanghai Pulmonary Hospital, Shanghai, China
22 clinical trials
11 abstracts
1 poster
Abstract
Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.Org: Shanghai Chest Hospital, Hunan Cancer Hospital, Department of Pulmonary Medicine, Department of Thoracic Surgery and Oncology, Cancer Hospital of the University of Chinese Academy of Sciences,
Abstract
Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC).Org: Shanghai Pulmonary Hospital, Shanghai, China, AOU San Luigi, University of Torino, Hospital Ramón y Cajal, University Hospitals KU Leuven,
Clinical trial
Efficacy and Safety of Toripalimab Combined With SBRT in the Neoadjuvant Treatment for Operable or Potentially Operable Non-small Cell Lung Cancer in Stage IIA to IIIBStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
Prediction of Immunotherapy Efficacy Based on Transcriptome of CX3CR1+T Cell in Peripheral BloodStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Abstract
Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Clinical trial
Efficacy and Safety of Airway Clearance Technique by Oscillation and Lung Expansion in Patients With BronchiectasisStatus: Recruiting, Estimated PCD: 2025-09-01
Abstract
Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Pulmonary and Critical Care Medicine,
Abstract
Reducing the risk of grade 3 or greater radiation pneumonitis after radical radiotherapy to the lung.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine,
Abstract
Phase I clinical study of FC084CSA, a high selective AXL kinase inhibitor that ameliorates tumor microenvironment and augments the effectivity of immunotherapy.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech,
Clinical trial
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2030-11-01
Clinical trial
Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): Study Protocol for a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Neoadjuvant Camrelizumab Plus Apatinib or Platinum-based Chemotherapy for Potentially Resectable (Resectable and Initially Unresectable) II-III Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-29
Clinical trial
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 TrialStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Randomized Phase II StudyStatus: Terminated, Estimated PCD: 2022-09-30
Clinical trial
Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung CancerStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III Driven Gene Mutation Negative Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2023-09-15
Clinical trial
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive Non-Small Cell Lung Cancer: A Single Arm, Exploratory TrialStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 TrialStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Neoadjuvant PD-1 Inhibitor (Tislelizumab) Plus Chemotherapy in Patients With Limited-stage Small-cell Lung Cancer: an Open-lable, Single-arm, Phase 2 TrialStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-08-01
Clinical trial
Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial TumorStatus: Recruiting, Estimated PCD: 2023-09-30
Clinical trial
Study on the Efficacy and Safety of KN046 Combined With Acitinib as a Neoadjuvant Therapy in Resectable Stage IB-IIIB Non-small Cell Lung Cancer (NSCLC) PatientsStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 TrialStatus: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer: A Single-Arm, Open-Label, Phase II Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase II Clinical Study of Cadonilimab in Combination With Chemotherapy as First-Line Treatment for PD-L1 Negative Advanced Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-09-04
Abstract
Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, National Taiwan University Hospital Yunlin Branch, National Taiwan University Cancer Center/Hospital, Taipei Veterans General Hospital, Chang Gung Memorial Hospital at Linkou and Chang Gung University,
Abstract
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The Second Hospital Affiliated to Air Force Medical University, Qilu Pharmaceutical,
Abstract
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.Org: Shanghai Pulmonary Hospital, Shanghai, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Bengbu Medical College, Shanghai Chest Hospital, Jiaotong University,
Abstract
Application of a contralateral esophageal-sparing technique to reduce radiation esophagitis in limited-stage small cell lung cancer treated with twice-daily radiotherapy and concurrent chemotherapy.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Henan Cancer Hospital,
Clinical trial
Phase II Clinical Study of Almonertinib in Combination With Lastet in the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With EGFR MutationsStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Exploratory Clinical Study of SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line TreatmentStatus: Not yet recruiting, Estimated PCD: 2027-06-15
Clinical trial
A Multicenter Clinical Study of LM-108 Antibody in Combination With Sintilimab for Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-06-12